XEOS MEDICAL
ActiveSummary
The annual accounts of XEOS MEDICAL for financial year 2025 show a net loss of 79% of total assets and of 698% of the equity at the start of that year. The 2025 annual accounts show equity of €4.0m and a net result of -€4.3m. Equity has been growing by about 11% per year since 2020. Its solvency ranks better than 79% of 818 sector peers (NACE 74, financial year 2025). The company has been active since 2019 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
Official details
Source: KBO- Status
- Active since 26-11-2019 Normal situation
- Registered office
- 17 active companies are registered at this address 2 started in the 12 months before. Source: KBO register, as of 2 November 2026.
- Activity
- Other professional, scientific and technical activities NACE 74999and 2 others
- Joint committee
- 200 Aanvullend Paritair Comité voor de bedienden · annual accounts 2025
- Establishment unit
- 2.296.795.989 9051 Gent, since 26-11-2019
- Financial year end
- 31 December
- Peppol
- Reachable since 29-07-2025
Board and ownership
Board
- Dr. Vincent Keereman, NeurologieManaging director
- Guido Van Der SchuerenDirector · since 12-12-2019
- Keereman, PatrickDirector · since 12-12-2019
Shareholders
- POWERGRAPH15.98%· score 832025 annual accounts of POWERGRAPH
- CHARLOTTEact of 30-01-2026
- DE PEERDEBOS· score 93act of 30-01-2026
- Holdings
- Shares in 1 company Xeos Medical Inc
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.1%
Annual accounts 2025
- Gross margin
- -€1.5m
- ▼ 24.4%
- Loss
- €4.3m
- ▲ 17.6%
- Equity
- €4.0m
- ▲ 548%
- Total assets
- €5.5m
- ▲ 97.9%
- Employees on 31-12-2025
- 23
- ▼ 4.2%
Turnover not published (abbreviated or micro format)
Score breakdownraises riskCapped at 59: a net loss of at least half of total assets or of the equity at the start of the financial yearLoss of €4.3m, the second in a row (financial year 2025)lowers riskLiquidity: current ratio 3.69, cash €3.3mSector: Other professional, scientific and technical activities (NACE 74)Equity €4.0m (73.2% of total assets)Show the evidence
Checked score
Score 2025
57
/ 100
Fair
Probability in this band: 1.5% to 4.2%
Financially stronger than 70% of small companies in other professional activities (NACE 74)
A net loss of at least half of total assets or of the equity at the start of the financial year caps the score at 59. Every signal that counts is listed under Signals.
Financial strength · tick: 2024
Strong
Solvency
98+51
equity 73.2% of total assets
Liquidity
92+38
short-term debt 23.6% · cash 60.2%
Profitability
0=
return on assets -78.8%
Bankruptcy probability within 12 months
0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.4%
01-2025: 0.4%● unchanged vs 12-2024
02-2025: 0.4%● unchanged vs 01-2025
03-2025: 0.5%▲ +0.1 percentage points vs 02-2025
04-2025: 0.6%▲ +0.1 percentage points vs 03-2025
05-2025: 0.6%● unchanged vs 04-2025
06-2025: 0.6%● unchanged vs 05-2025
07-2025: 1.1%▲ +0.5 percentage points vs 06-2025
08-2025: 1.1%● unchanged vs 07-2025
09-2025: 1.1%● unchanged vs 08-2025
10-2025: 1.1%● unchanged vs 09-2025
11-2025: 1.2%▲ +0.1 percentage points vs 10-2025
12-2025: 1.2%● unchanged vs 11-2025
01-2026: 1.2%● unchanged vs 12-2025
02-2026: 1.2%● unchanged vs 01-2026highest value
03-2026: 0.8%▼ -0.4 percentage points vs 02-2026
04-2026: 0.8%● unchanged vs 03-2026
05-2026: 0.9%▲ +0.1 percentage points vs 04-2026
06-2026: 0.1%▼ -0.8 percentage points vs 05-2026lowest value
07-2026: 0.1%● unchanged vs 06-2026lowest value
08-2026: 0.1%● unchanged vs 07-2026lowest value
09-2026: 0.1%● unchanged vs 08-2026lowest value
10-2026: 0.1%● unchanged vs 09-2026lowest value
11-2026: 0.1%● unchanged vs 10-2026lowest value
Credit of up to €220,000 on 30-day terms, only on tighter conditions
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity is ample, with a current ratio of 3.69 (2.17 in 2024), above the usual 1.5. Short-term debt is 23.6% and cash 60.2% of total assets. 26.8% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 74, small). It does better than 83% of them on solvency, 94% on liquidity, 4% on profitability and 99% on growth.
The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-05-2026, 65 days ahead of the deadline.
NBB · 6 filingsDeviation from the deadline
2025
65 days early
2024
50 days early
2023
51 days early
2022
75 days early
2021
33 days early
2020
51 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 6 accounts on average 54 days before the deadline. In the sector (NACE 74), the median for financial year 2024 was 3 days before the deadline, and 38% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 11 June (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
02-11-2026 today31-12-2026 year end31-07-2027 deadline
Key points
- Risk: 6 loss-making years in a rowloss in financial year 2025 -€4.3m View
- Positive: Equity rose in 2025from €620,934 to €4.0m ▲ 548% View
- Caution: Lower net result than 95% of companies in other professional activitiessector median €12,609 · 816 companies -€4.3m View
- Board changedlatest change 30-01-2026 · 7 in office 4 joined · 3 left View
- Positive: Always filed on timeaccounts within the deadline every year 6 years View
- Flemish supportawarded from 2022 to 2025 €896,321 View
Recent changes
- · Gazette deed Resignations: Santens, Jan Baptiste, Levrau, Laurence and Nuclear Imaging ConsultancyAppointments: Keereman, Patrick, Mastelinck, Walter and 4 others
- · Gazette deed Reappointments: Guido Van Der Schueren, Jan Baptiste Santens and 4 othersPermanent representatives: Roel Van Holen and Vincent Keereman
- · Gazette deed Capital decrease of €4,722,000 to €4,355,000
Companies linked to XEOS MEDICAL
Comparable companies
These companies have the same main activity as XEOS MEDICAL: other professional, scientific and technical activities (NACE 74999). They are comparable in size and age: total assets between €2.8m and €16m, founded between 2016 and 2021.
| Company | Total assets | Gross margin |
|---|---|---|
| XEOS MEDICAL Gent | €5.5m | -€1.5m |
| JuuNoo Anzegem | €7.5m | -€0.3m |
| HELEXIA BELGIUM Antwerpen | €5.0m | -€0.6m |
| C-Battery Temse | €8.5m | -€0.4m |
| Blue Foot Membranes Lommel | €16.1m | -€0.5m |
| IDEVAX Wijnegem | €3.9m | -€0.2m |
| QustomDot Gent | €2.8m | -€0.6m |
Key facts about XEOS MEDICAL
- What is the company number of XEOS MEDICAL?
- The company number of XEOS MEDICAL is 0738.435.957. The VAT number is the same number with BE in front: BE 0738.435.957.
- Where is XEOS MEDICAL based?
- The registered office is at Kortrijksesteenweg 1084, 9051 Gent.Company details
- What does XEOS MEDICAL do?
- According to the KBO register, the main activity is other professional, scientific and technical activities (NACE 74999).
- What is the legal form of XEOS MEDICAL?
- The legal form of XEOS MEDICAL is Public limited company (NV).
- When was XEOS MEDICAL founded?
- XEOS MEDICAL was founded on 26-11-2019.
- Is XEOS MEDICAL still active?
- Yes, XEOS MEDICAL is an active enterprise in the KBO register.
- How many employees does XEOS MEDICAL have?
- XEOS MEDICAL had an average of 23.9 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does XEOS MEDICAL fall under?
- In its 2025 annual accounts, XEOS MEDICAL states joint committee 200 (Aanvullend Paritair Comité voor de bedienden).
- What is the turnover of XEOS MEDICAL?
- The annual accounts for financial year 2025 state no turnover. The abbreviated or micro format does not require it.
- Is XEOS MEDICAL profitable?
- In financial year 2025, XEOS MEDICAL made a loss of €4.3m.
- Where can I find the annual accounts of XEOS MEDICAL?
- XEOS MEDICAL filed 6 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of XEOS MEDICAL due?
- XEOS MEDICAL must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies
See how customers, suppliers and banks see your own company and what to improve first.